Skip to main content

Research Repository

Advanced Search

Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody

Soliman, Caroline; Guy, Andrew J.; Chua, Jia Xin; Vankemmelbeke, Mireille; McIntosh, Richard S.; Eastwood, Sarah; Truong, Vi Khanh; Elbourne, Aaron; Spendlove, Ian; Durrant, Lindy G.; Ramsland, Paul A.

Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody Thumbnail


Authors

Caroline Soliman

Andrew J. Guy

Jia Xin Chua

Mireille Vankemmelbeke

Richard S. McIntosh

Sarah Eastwood

Vi Khanh Truong

Aaron Elbourne

Lindy G. Durrant

Paul A. Ramsland



Abstract

Immunotherapy has been successful in treating many tumour types. The development of additional tumour-antigen binding monoclonal antibodies (mAbs) will help expand the range of immunotherapeutic targets. Lewis histo-blood group and related glycans are overexpressed on many carcinomas, including those of the colon, lung, breast, prostate and ovary, and can therefore be selectively targeted by mAbs. Here we examine the molecular and structural basis for recognition of extended Lea and Lex containing glycans by a chimeric mAb. Both the murine (FG88.2) IgG3 and a chimeric (ch88.2) IgG1 mAb variants showed reactivity to colorectal cancer cells leading to significantly reduced cell viability. We determined the X-ray structure of the unliganded ch88.2 fragment antigen-binding (Fab) containing two Fabs in the unit cell. A combination of molecular docking, glycan grafting and molecular dynamics simulations predicts two distinct subsites for recognition of Lea and Lex trisaccharides. While light chain residues were exclusively used for Lea binding, recognition of Lex involved both light and heavy chain residues. An extended groove is predicted to accommodate the Lea–Lex hexasaccharide with adjoining subsites for each trisaccharide. The molecular and structural details of the ch88.2 mAb presented here provide insight into its cross-reactivity for various Lea and Lex containing glycans. Furthermore, the predicted interactions with extended epitopes likely explains the selectivity of this antibody for targeting Lewis-positive tumours.

Citation

Soliman, C., Guy, A. J., Chua, J. X., Vankemmelbeke, M., McIntosh, R. S., Eastwood, S., …Ramsland, P. A. (2020). Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody. Biochemical Journal, 477(17), 3219-3235. https://doi.org/10.1042/bcj20200454

Journal Article Type Article
Acceptance Date Aug 13, 2020
Online Publication Date Sep 10, 2020
Publication Date Sep 18, 2020
Deposit Date Nov 26, 2020
Publicly Available Date Sep 11, 2021
Journal Biochemical Journal
Print ISSN 0264-6021
Electronic ISSN 1470-8728
Publisher Portland Press
Peer Reviewed Peer Reviewed
Volume 477
Issue 17
Pages 3219-3235
DOI https://doi.org/10.1042/bcj20200454
Keywords Cell Biology; Biochemistry; Molecular Biology
Public URL https://nottingham-repository.worktribe.com/output/5071831
Publisher URL https://portlandpress.com/biochemj/article-abstract/477/17/3219/226072/Molecular-and-structural-basis-for-Lewis-glycan?redirectedFrom=fulltext